These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33086850)

  • 21. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368
    [No Abstract]   [Full Text] [Related]  

  • 22. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
    Glassman AR; Wells JA; Josic K; Maguire MG; Antoszyk AN; Baker C; Beaulieu WT; Elman MJ; Jampol LM; Sun JK
    Ophthalmology; 2020 Sep; 127(9):1201-1210. PubMed ID: 32402554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Awh CC; Kunimoto DY; Marcus DM; Wroblewski JJ; King J;
    JAMA; 2017 May; 317(20):2072-2087. PubMed ID: 28492910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
    Bro T; Hägg S
    Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
    Ehlers JP; Yeh S; Maguire MG; Smith JR; Mruthyunjaya P; Jain N; Kim LA; Weng CY; Flaxel CJ; Schoenberger SD; Kim SJ
    Ophthalmology; 2022 Jan; 129(1):88-99. PubMed ID: 34446301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.
    Ozkaya A; Demir G; Kirmaci A
    Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
    Jampol LM; Glassman AR; Bressler NM
    JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients.
    Ruiz-Moreno JM; de Andrés-Nogales F; Oyagüez I
    BMC Ophthalmol; 2020 Sep; 20(1):371. PubMed ID: 32943041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey.
    Yilmaz M; Citirik M; Rahmanlar H; Alkan A; Gursoz H
    Rom J Ophthalmol; 2022; 66(4):304-309. PubMed ID: 36589330
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
    Liberski S; Wichrowska M; Kocięcki J
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Management of aflibercept in routine clinical practice].
    Cabrera López F
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():29-34. PubMed ID: 25925049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
    Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies.
    Xiao K; Li FZ; Liang SZ; Wang J; Qian C; Wan GM
    Ann Pharmacother; 2020 Aug; 54(8):750-756. PubMed ID: 32005079
    [No Abstract]   [Full Text] [Related]  

  • 39. Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial.
    Gurudas S; Patrao N; Nicholson L; Sen P; Ramu J; Sivaprasad S; Hykin P
    JAMA Ophthalmol; 2022 Feb; 140(2):143-150. PubMed ID: 34989804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
    Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.